<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03057002</url>
  </required_header>
  <id_info>
    <org_study_id>STU 102016-046</org_study_id>
    <nct_id>NCT03057002</nct_id>
  </id_info>
  <brief_title>UTSW HP [13-C] Pyruvate Injection in HCM</brief_title>
  <acronym>HPHCM</acronym>
  <official_title>Detection of Regional Myocardial Metabolic Changes in Patients With Hypertrophic Cardiomyopathy Using Hyperpolarized Carbon 13 Magnetic Resonance Spectroscopic Imaging (MRSI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study the investigators propose to detect early mitochondrial metabolic changes in&#xD;
      the heart in patients with a positive genotype and phenotype for Hypertrophic Cardiomyopathy&#xD;
      (HCM) using a novel hyperpolarized [1-13C]pyruvate Magnetic Resonance Imaging (MRI)&#xD;
      methodology.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study the investigators propose to detect early mitochondrial metabolic changes in&#xD;
      the heart in patients with a positive genotype and phenotype for HCM using a novel&#xD;
      hyperpolarized [1-13C]pyruvate MRI methodology. Carbon-13 is a stable isotope (not&#xD;
      radioactive) that makes up approximately 1.1% of all natural carbon. Carbon-13 has a non-zero&#xD;
      spin quantum number that allows the investigation of carbon containing substances using&#xD;
      magnetic resonance. However, compared with other analytical methods, carbon-13 magnetic&#xD;
      resonance has been limited by an intrinsically low sensitivity [2}.&#xD;
&#xD;
      Recent experimental studies suggest that altered energy substrate metabolism may precede&#xD;
      structural changes in myocardial hypertrophy. A better understanding of the myocardial&#xD;
      metabolic changes in HCM is important, as the elucidation of such changes may precede the&#xD;
      clinical development of myocardial fibrosis and malignant arrhythmias. Hyperpolarized&#xD;
      [1-13C]pyruvate and its cellular metabolic flux can be assessed with a more than 10,000-fold&#xD;
      higher sensitivity compared to traditional methods. The aim of this pilot study is to test&#xD;
      the hypothesis that patients with HCM present focal alterations in myocardial hyperpolarized&#xD;
      [1-13C]pyruvate flux.&#xD;
&#xD;
      To achieve this aim the investigators will assess myocardial metabolic changes in HCM&#xD;
      subjects with a positive HCM genotype and phenotype (n=5) and in healthy control subjects&#xD;
      (n=5) who are matched for age, sex, and Body Mass Index (BMI). Total target enrollment will&#xD;
      be set at 15 subjects to allow for attrition and screen failures.&#xD;
&#xD;
      Cardiac function and structure will be evaluated with MRI (proton imaging) before and after&#xD;
      contrast administration. Then myocardial metabolism will be assessed utilizing MRS (carbon&#xD;
      spectroscopy) before and after intravenous injection with hyperpolarized [1-13C]pyruvate. The&#xD;
      study agent, hyperpolarized [1-13C]pyruvate, will be administered under a Food and Drug&#xD;
      Administration (FDA) Investigational New Drug (IND), currently in review process, PI Dr.&#xD;
      Craig Malloy.&#xD;
&#xD;
      Human preliminary data are essential to secure larger scale funding required for clinical&#xD;
      studies. The identification of mitochondrial metabolic changes preceding replacement fibrosis&#xD;
      and malignant arrhythmias may generate a paradigm shift to early detection and more targeted&#xD;
      treatment of HCM with potentially improved clinical outcomes. Cardiac focused applications at&#xD;
      the Advanced Imaging Research Center, genetic disease diagnosis at the Eugene McDermott&#xD;
      Center for Human Genetics and the development of a dedicated HCM Clinic at the UT&#xD;
      Southwestern Medical Center offer today a unique opportunity to lead globally the&#xD;
      translational scientific efforts in this field.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Study temporarily on hold due to COVID19&#xD;
  </why_stopped>
  <start_date type="Actual">May 1, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Hyperpolarized [1-13C]pyruvate flux</measure>
    <time_frame>Screening (Baseline) and 1 day of Study Visit</time_frame>
    <description>Measurement of change in myocardial hyperpolarized [1-13C]pyruvate flux during Magnetic Resonance Spectroscopic Imaging.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Cardiomyopathy, Hypertrophic</condition>
  <arm_group>
    <arm_group_label>HCM Group</arm_group_label>
    <description>HCM patients will be observed for myocardial hyperpolarized 13C-pyruvate flux during magnetic resonance spectroscopic imaging.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <description>Healthy control subjects will be observed for myocardial hyperpolarized 13C-pyruvate flux during magnetic resonance spectroscopic imaging.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyperpolarized 13C-Pyruvate</intervention_name>
    <description>All subjects will be observed for myocardial hyperpolarized [1-13C]pyruvate flux during magnetic resonance spectroscopic imaging.</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>HCM Group</arm_group_label>
    <other_name>HP [1-13C]pyruvate</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        5 Hypertrophic cardiomyopathy (HCM) Patients and 5 Healthy Controls&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria for Control Subjects:&#xD;
&#xD;
          -  Subjects who are 18 through 60 years of age.&#xD;
&#xD;
          -  Subjects who have the ability to understand and the willingness to sign a written&#xD;
             informed consent.&#xD;
&#xD;
          -  While all races and ethnicities will be included, subjects must be able to read and&#xD;
             speak the English language. Once the protocol is established, Spanish-speaking&#xD;
             participants will be included.&#xD;
&#xD;
          -  Women of child-bearing potential must agree to use adequate contraception (hormonal or&#xD;
             barrier method of birth control; abstinence) prior to study entry, for the duration of&#xD;
             study participation. Should a woman become pregnant or suspect she is pregnant while&#xD;
             participating in this study, she should inform her treating physician immediately.&#xD;
&#xD;
        Inclusion Criteria for HCM subjects:&#xD;
&#xD;
          -  Definitive diagnosis of HCM by genotype and imaging which demonstrates abnormal Left&#xD;
             Ventricular (LV) wall thickness in the absence of other cause (Unexplained maximal&#xD;
             wall thickness &gt;15 mm in any myocardial segment [6-8]).&#xD;
&#xD;
          -  Subjects who are 18 through 60 years of age.&#xD;
&#xD;
          -  Subjects who have the ability to understand and the willingness to sign a written&#xD;
             informed consent.&#xD;
&#xD;
          -  While all races and ethnicities will be included, subjects must be able to read and&#xD;
             speak the English language. Once the protocol is established, Spanish-speaking&#xD;
             participants will be included.&#xD;
&#xD;
          -  Women of child-bearing potential must agree to use adequate contraception (hormonal or&#xD;
             barrier method of birth control; abstinence) prior to study entry and for the duration&#xD;
             of study participation. Should a woman become pregnant or suspect she is pregnant&#xD;
             while participating in this study, she should inform her treating physician&#xD;
             immediately.&#xD;
&#xD;
        Exclusion criteria for Controls and HCM Subjects:&#xD;
&#xD;
          -  Subjects who are receiving any other investigational agents.&#xD;
&#xD;
          -  Intercurrent illness including, but not limited to, ongoing or active infection,&#xD;
             uncontrolled chronic diseases such as hypertension, lung disease, liver disease,&#xD;
             kidney disease, diabetes, symptomatic congestive heart failure, unstable angina&#xD;
             pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would&#xD;
             limit compliance with study requirements.&#xD;
&#xD;
          -  Subjects who are taking thyroid hormone replacements, have a history of alcohol abuse&#xD;
             or illicit drug use.&#xD;
&#xD;
          -  Subjects who have contraindication to contrast enhanced MRI examination.&#xD;
&#xD;
        Contraindications to MRI examinations include:&#xD;
&#xD;
          -  Medically unstable&#xD;
&#xD;
          -  Heart failure&#xD;
&#xD;
          -  Severe Left Ventricular Outflow Tract (LVOT) obstruction&#xD;
&#xD;
          -  Unstable angina&#xD;
&#xD;
          -  Child bearing&#xD;
&#xD;
          -  Lactating&#xD;
&#xD;
          -  Any contraindication per MRI Screening Form including&#xD;
&#xD;
          -  Implants contraindicated at 3Tesla, pacemakers&#xD;
&#xD;
          -  Implantable Cardioverter Defibrillator (ICD)&#xD;
&#xD;
          -  Claustrophobia&#xD;
&#xD;
          -  Since each subject is receiving a gadolinium based contrast agent intravenously:&#xD;
&#xD;
          -  eGFR â‰¤ 30 mL/min/1.73m2&#xD;
&#xD;
          -  Sickle cell disease&#xD;
&#xD;
          -  Hemolytic anemia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vlad G Zaha, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Advanced Imaging Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT Southwestern Medical Center - Advanced Imaging Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 10, 2017</study_first_submitted>
  <study_first_submitted_qc>February 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2017</study_first_posted>
  <last_update_submitted>March 3, 2021</last_update_submitted>
  <last_update_submitted_qc>March 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Vlad Zaha</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Hypertrophic</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

